Previous close | 2.8000 |
Open | 2.8000 |
Bid | 0.2000 |
Ask | 10.0000 |
Strike | 390.00 |
Expiry date | 2025-01-17 |
Day's range | 2.8000 - 2.8000 |
Contract range | N/A |
Volume | |
Open interest | 2 |
On Thursday, the European Commission granted marketing authorization under exceptional circumstances and maintained orphan designation for Biogen Inc’s (NASDAQ:BIIB) Qalsody (tofersen) for amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 gene (SOD1-ALS). Qalsody is the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND). SOD1-ALS is an ultra-rare genetic form of ALS estimated to affe
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe